Jin Medical International Ltd. (NASDAQ: ZJYL) confirmed that it has regained compliance with Nasdaq’s minimum bid‑price rule, a milestone that averts the possibility of delisting. The company achieved the required $1.00 per share closing bid price for more than ten consecutive business days, a threshold that Nasdaq requires for continued listing.
The compliance announcement follows a 1‑for‑20 reverse stock split that took effect on March 16 2026. The split was a strategic move to lift the per‑share price and bring the stock back into the $1.00 range, addressing the deficiency that had been flagged by Nasdaq on May 2 2025. The reverse split reduced the number of shares outstanding while increasing the share price, thereby aligning the stock with Nasdaq’s listing standards without altering the company’s underlying equity value.
Jin Medical’s core business remains the design, development, manufacturing, and marketing of wheelchairs and living‑aid products. The company operates two manufacturing plants in China and is building a larger facility in Chuzhou, Anhui Province. In the trailing twelve months, the company reported sales of $10.806 million, net income of $1.280 million, and earnings per share of $0.010, reflecting a year‑over‑year revenue decline of 11.98% for FY 2025. Despite the compliance win, the company’s market cap sits at $15.5 million, with cash and short‑term investments of $29.6 million offsetting debt of $18.8 million, resulting in a debt‑to‑equity ratio of 63.7% and an interest coverage ratio of –0.8.
Market reaction to the compliance news was muted, with analysts noting that while the delisting risk is removed, the company’s broader financial challenges remain. The stock had been trading below $1.00 for several months, and the reverse split and compliance do not address underlying revenue weakness or the company’s modest profitability. Investors will likely view the compliance as a necessary but insufficient step toward restoring confidence in Jin Medical’s long‑term prospects.
The regulatory milestone underscores the importance of maintaining Nasdaq’s listing standards, but it also highlights the company’s ongoing need to strengthen its financial performance and operational execution. The reverse split and compliance are tactical measures; sustainable growth will require continued focus on product innovation, market expansion, and cost discipline. Investors should monitor the company’s future earnings releases and guidance for indications of whether these measures translate into improved profitability and shareholder value.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.